Latest Heart News
WEDNESDAY, Nov. 5, 2014 (HealthDay News) -- Arthritis pain relievers known as COX-2 inhibitors, including Celebrex and Lodine, are associated with an increased risk of dying within a month after a stroke, according to a new study.
However, while the study found an association between use of these painkillers and death in stroke patients, it did not prove cause-and-effect.
Other types of nonsteroidal anti-inflammatory painkillers (NSAIDs) -- including ibuprofen (Advil, Motrin) and naproxen (Aleve) -- weren't linked to an increased risk of death after stroke, the study authors said.
In the new study -- based on more than 100,000 people hospitalized for a first stroke between 2004 and 2012-- the investigators wanted to see if the painkillers affected recovery from a stroke.
The researchers found that use of Celebrex prior to hospitalization for ischemic stroke was associated with a 19 percent increase in risk of death within a month, compared with non-use of the drug.
Ischemic stroke, the most common type of stroke, is caused by a clot that blocks blood flow to the brain.
"Much of this result came from new users of the drugs, who were 42 percent more likely to die from stroke than those who were not taking the drugs," said lead researcher Dr. Morten Schmidt, the cardiovascular research coordinator at Aarhus University Hospital.
"The results were also stronger for those taking the older COX-2 inhibitors," he added.
The older drugs -- for example, Lodine (etodolac) -- raised the risk of dying from stroke by 53 percent, the researchers reported.
The report was published in the Nov. 5 online edition of the journal Neurology.
Of the more than 100,000 stroke patients the researchers looked at, 11 percent used painkillers prior to admission and 8 percent were former users.
"There are several cardiovascular risks to consider when prescribing NSAIDs, in particular COX-2 inhibitors," Schmidt said.
"Efforts should be made to ensure people with a higher risk of stroke are not prescribed these medications when other options are available," he said.
Copyright © 2014 HealthDay. All rights reserved.